trending Market Intelligence /marketintelligence/en/news-insights/trending/8V9j1f3E3oCwi3732IVuoA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Innate Pharma raises $79.1M from Nasdaq IPO, private placement

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Innate Pharma raises $79.1M from Nasdaq IPO, private placement

Innate Pharma SA raised about $79.1 million in gross proceeds from an IPO of its American depositary shares and a concurrent private placement.

The Marseille, France-based biotechnology company sold 9,922,227 American depositary shares — each representing one ordinary share — in its IPO on the Nasdaq Global Select market. The ADSs were priced at $5.50 each.

Innate also sold 4,452,773 ordinary shares in Europe and other countries outside the U.S. in a concurrent private placement. The ordinary shares under the placement were sold at €4.97 each.

A total of 14,375,000 new ordinary shares were sold to investors under the IPO and concurrent placement.

Innate Pharma's shares are listed on the Euronext Paris under the IPH ticker symbol, while its ADSs are listed on the Nasdaq Global Select market under the IPHA symbol. The ADS began trading on the U.S. stock exchange Oct. 17.

Citigroup Global Markets Inc., SVB Leerink LLC and Evercore Group LLC were joint book runners for the U.S. offering, while Citigroup Global Markets Ltd was global coordinator for the placement. Namsen Capital was capital markets advisor to Innate Pharma.

Innate Pharma previously said about $30 million of the proceeds will be used to build commercial capabilities for its drug Lumoxiti in the U.S. and EU, subject to approval. The U.S. Food and Drug Administration in September 2018 approved the therapy for treating a type of blood cancer.

Innate licensed Lumoxiti from AstraZeneca PLC in October 2018.

Another $55 million will be directed toward the expansion and advancement of Innate's pipeline.